Literature DB >> 17560312

Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts.

Nadera J Sweiss1, James Curran, Robert P Baughman.   

Abstract

Tumor necrosis factor is a potent cytokine involved in the inflammatory process of many diseases. Agents that block tumor necrosis factor have been used in the treatment of various immune-mediated diseases, including rheumatoid arthritis, Crohn disease, psoriatic arthritis, and ankylosing spondylitis. Sarcoidosis is an immune-mediated inflammatory disorder of unknown etiology characterized by the formation of noncaseating granulomas. Tumor necrosis factor plays a major role in the inflammatory process seen in sarcoidosis. Sarcoidosis therapies with activity against tumor necrosis factor and specific anti-tumor necrosis factor therapies have been used with variable success. The long-term safety and efficacy of such therapies are yet to be determined in well-designed clinical trials with long-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560312     DOI: 10.1016/j.clindermatol.2007.03.012

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  9 in total

1.  Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab.

Authors:  Peter Korsten; Nadera J Sweiss; Ulf Nagorsnik; Timothy B Niewold; Hermann-Josef Gröne; Oliver Gross; Gerhard A Müller
Journal:  Am J Kidney Dis       Date:  2010-10-25       Impact factor: 8.860

Review 2.  Cytokine modulators in the treatment of sarcoidosis.

Authors:  E Bargagli; C Olivieri; P Rottoli
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

3.  Rituximab in the treatment of refractory pulmonary sarcoidosis.

Authors:  Nadera J Sweiss; Elyse E Lower; Mehdi Mirsaeidi; Steven Dudek; Joe G N Garcia; David Perkins; Patricia W Finn; Robert P Baughman
Journal:  Eur Respir J       Date:  2014-01-31       Impact factor: 16.671

Review 4.  Rheumatologic manifestations of sarcoidosis.

Authors:  Nadera J Sweiss; Karen Patterson; Ray Sawaqed; Umair Jabbar; Peter Korsten; Kyle Hogarth; Robert Wollman; Joe G N Garcia; Timothy B Niewold; Robert P Baughman
Journal:  Semin Respir Crit Care Med       Date:  2010-07-27       Impact factor: 3.119

5.  Hypothesis: sarcoidosis is a STAT1-mediated disease.

Authors:  James T Rosenbaum; Sirichai Pasadhika; Elliott D Crouser; Dongseok Choi; Christina A Harrington; Jinnell A Lewis; Carrie R Austin; Tessa N Diebel; Emily E Vance; Rita M Braziel; Justine R Smith; Stephen R Planck
Journal:  Clin Immunol       Date:  2009-05-22       Impact factor: 3.969

6.  Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study.

Authors:  Amit R Patel; Michael R Klein; Sonal Chandra; Kirk T Spencer; Jeanne M Decara; Roberto M Lang; Martin C Burke; Edward R Garrity; D Kyle Hogarth; Stephen L Archer; Nadera J Sweiss; John F Beshai
Journal:  Eur J Heart Fail       Date:  2011-08-02       Impact factor: 17.349

7.  Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestry.

Authors:  Nadera J Sweiss; Wei Zhang; Beverly S Franek; Silvia N Kariuki; David R Moller; Karen C Patterson; Peggy Bennett; Lakshmi R Girijala; Vaisak Nair; Robert P Baughman; Joe G N Garcia; Timothy B Niewold
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

Review 8.  Subcutaneous sarcoidosis: a rare involvement of the paralateral nasal region.

Authors:  C Bianchini; E Tosin; A Ciorba; S Pelucchi; A Pastore
Journal:  Acta Otorhinolaryngol Ital       Date:  2010-12-29       Impact factor: 2.124

Review 9.  Musculoskeletal involvement in sarcoidosis.

Authors:  Akasbi Nessrine; Abourazzak Fatima Zahra; Harzy Taoufik
Journal:  J Bras Pneumol       Date:  2014 Mar-Apr       Impact factor: 2.624

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.